Oncology drugs are medications used to treat cancer by targeting and destroying cancer cells. They include chemotherapy, targeted therapy, immunotherapy, and hormone therapy, helping manage or cure various cancers. Read more: https://wemarketresearch.com/reports/oncology-drugs-market/1313 #OncologyDrugs #CancerTreatment #Chemotherapy #Immunotherapy #TargetedTherapy #CancerResearch #OncologyCare #CancerMedications #HealthInnovation #MedicalScience #PharmaUpdates #CancerAwareness #LifeSavingDrugs

#Antibody_Drug_Conjugates (ADCs) are a class of targeted cancer therapies that combine an antibody with a cytotoxic (cell-killing) drug. Read More: https://wemarketresearch.com/reports/antibody-drug-conjugates-market/132 #AntibodyDrugConjugates #ADCs #CancerTreatment #TargetedTherapy #Immunotherapy #CancerResearch #Oncology #PrecisionMedicine #Pharmaceuticals #Biopharma #CancerTherapy

Explore plasma exchange (plasmapheresis) for autoimmune diseases. Learn the procedure, benefits, risks, and understand pricing factors. Find your path to relief. https://www.vevioz.com/read-blog/300339_plasma-exchange-for-autoimmune-diseases-procedure-amp-pricing.html #PlasmaExchange #AutoimmuneDisease #Plasmapheresis #Immunotherapy #MedicalTreatment #HealthcareCost #AutoimmuneRelief #MedicalGuide #PatientEducation #HealthAwareness

Hematologic Malignancies Market Size to Reach USD 147.71 Billion by 2033 | Straits Research Hematologic Malignancies Market Trends & Growth | CAGR of 8.14% | Straits Research Report The global hematologic malignancies market was valued at USD 72.87 billion in 2024, and it is projected to grow from USD 78.99 billion in 2025 to USD 147.71 billion by 2033, exhibiting a CAGR of 8.14% during the forecast period from 2025 to 2033. This robust growth is driven by advancements in cancer therapies, increasing research funding, and rising incidences of hematologic cancers globally. Hematologic malignancies, such as leukemia, lymphoma, and multiple myeloma, continue to be major public health concerns, leading to strong market demand for novel therapies and innovative treatments. Market Definition:Hematologic malignancies refer to cancers that affect the blood, bone marrow, lymph, and lymphatic system. These malignancies include conditions such as leukemia, lymphoma, and multiple myeloma. Treatment for these cancers involves chemotherapy, immunotherapy, radiation, stem cell transplants, and targeted therapies. Hematologic malignancies are often aggressive, requiring advanced treatment methods to improve survival rates. The market is witnessing a surge in research and development activities focused on finding more effective and personalized treatment options, contributing to the sector's growth. Highlights of the Hematologic Malignancies Market: Market Growth: The hematologic malignancies market is expected to reach USD 147.71 billion by 2033, growing at a CAGR of 8.14% from 2025 to 2033. Rising Incidence of Hematologic Cancers: The increasing global prevalence of blood cancers such as leukemia, lymphoma, and myeloma is driving the demand for innovative treatment solutions. Advancements in Immunotherapy and Targeted Treatments: Growing adoption of immunotherapies and targeted drugs is revolutionizing the treatment landscape of hematologic malignancies, improving patient outcomes. Increased Research Investment: Substantial investments in R&D for hematologic malignancies therapies are accelerating the introduction of new and advanced treatments into the market. Expanding Healthcare Infrastructure in Emerging Economies: The growing healthcare infrastructure in regions like Asia-Pacific is contributing to the rising accessibility of treatments for hematologic malignancies. Key Players in the Hematologic Malignancies Market: Bristol-Myers Squibb Roche Holding AG Novartis AG Celgene Corporation (now part of Bristol-Myers Squibb) AbbVie Inc. Amgen Inc. Gilead Sciences, Inc. Sanofi S.A. Johnson & Johnson Eli Lilly and Company Dominated Region: The Asia-Pacific region currently dominates the hematologic malignancies market due to the rising healthcare expenditure, improving medical infrastructure, and increasing prevalence of hematologic cancers in the region. Countries such as China and India are expected to continue leading the market due to their growing populations and healthcare initiatives. Fastest Growing Region: The Europe region is the fastest-growing market for hematologic malignancies. With increasing awareness, improved healthcare services, and strong government support for cancer research, Europe is expected to see a significant rise in treatment demand, making it a key market for growth in the coming years. Segmentation: Access Detailed Segmentation @ https://straitsresearch.com/report/hematologic-malignancies-market/segmentation By Type of Cancer Leukemia Lymphoma Multiple Myeloma By Treatment Type Chemotherapy Immunotherapy Stem Cell Transplantation Targeted Therapy Radiotherapy By End-User Hospitals Cancer Centers Ambulatory Care Centers By Region North America Europe Asia-Pacific Latin America Middle East & Africa Questions Answered in the Report: For a full PDF sample copy of the report, visit @ https://straitsresearch.com/report/hematologic-malignancies-market/request-sample. For more information or customization before purchasing, visit @ https://straitsresearch.com/buy-now/hematologic-malignancies-market. Contact Us: Email: sales@straitsresearch.com Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)

Understanding How Immunotherapy Treatments Are Given to Patients Immunotherapy is given via injections, infusions, or pills, depending on the type and purpose. Treatments can target cancer cells or boost the immune system. Sessions are usually administered in clinics or hospitals. Your doctor will determine the best method based on your condition. Regular monitoring ensures effectiveness and minimizes side effects. To know more Visit here : http://www.cancersa.org.au/

Common Questions About Immunotherapy Answered When it comes to cancer treatment in Pune, immunotherapy has become a popular option. Dr. Pratik Patil, a renowned cancer specialist in Pune, is known for offering advanced immunotherapy to his patients. In this blog, we answer common questions about immunotherapy to help you better understand this treatment. What is Immunotherapy Treatment For? Immunotherapy is a sort of cancer treatment that utilizes the body’s immune system to battle cancer. It helps the immune system recognize and obliterate cancer cells. Dr. Pratik Patil explains that immunotherapy is frequently utilized for cancers like cellular breakdown in the lungs, melanoma, kidney cancer, and certain blood cancers. It is an effective option for patients who may not respond to traditional treatments like chemotherapy. What is the Cost of Immunotherapy? The cost of immunotherapy in Pune depends on the type of cancer and the number of sessions required. On average, the cost can range from ₹2 lakhs to ₹6 lakhs per cycle. Dr. Pratik Patil emphasizes the importance of discussing costs with your oncologist to plan your treatment effectively. Many hospitals in Pune also offer financial assistance programs. Is Immunotherapy for Cancer Successful? Immunotherapy has shown remarkable success in many cases. It can lead to long-term remission, especially in cancers like melanoma and lung cancer. As indicated by Dr. Pratik Patil, achievement relies upon factors like the type and stage of cancer, and the patient’s general wellbeing. Patients in Pune who have gone through immunotherapy under his consideration often report positive results. At What Stage of Cancer is Immunotherapy Used? Immunotherapy can be used at various stages of cancer. It is often recommended for advanced stages, such as stage 3 or stage 4 cancers, where other treatments may not be effective. Dr. Pratik Patil states that early stages can also benefit from immunotherapy, depending on the type of cancer and the patient’s condition. Cancer treatment in Pune is becoming more advanced, thanks to options like immunotherapy. Is Chemo Cheaper than Immunotherapy? Yes, chemotherapy is generally cheaper than immunotherapy. While chemotherapy costs in Pune may range from ₹50,000 to ₹1.5 lakhs per cycle, immunotherapy is more expensive. However, Dr. Pratik Patil highlights that the benefits of immunotherapy, including fewer side effects and improved quality of life, often justify the higher cost. Can Stage 4 Cancer be Cured with Immunotherapy? While immunotherapy may not ensure a remedy for stage 4 cancer, it can fundamentally delay life and work on its quality. Dr. Pratik Patil, Medical oncologists explains that numerous patients in Pune with advanced cancers have experienced remarkable outcomes with immunotherapy. The treatment can shrink tumors, postpone sickness movement, and, at times, lead to abatement. How Long Can a Cancer Patient Live with Immunotherapy? The survival rate with immunotherapy varies. A few patients live for a very long time subsequent to beginning treatment. Dr. Pratik Patil shares that patients in Pune have revealed survival times, particularly for cancers like melanoma and non-small cell lung cancer. The long-term benefits depend on how the cancer responds to the treatment. What Happens After Immunotherapy Ends? After immunotherapy ends, patients may need regular follow-ups to monitor their progress. Side effects like fatigue or skin reactions may take time to subside. Dr. Pratik Patil advises his Pune patients to maintain a healthy lifestyle and attend all follow-up appointments. These steps ensure that any recurrence or side effects are managed promptly.

Common Questions About Immunotherapy Answered When it comes to cancer treatment in Pune, immunotherapy has become a popular option. Dr. Pratik Patil, a renowned cancer specialist in Pune, is known for offering advanced immunotherapy to his patients. In this blog, we answer common questions about immunotherapy to help you better understand this treatment. What is Immunotherapy Treatment For? Immunotherapy is a sort of cancer treatment that utilizes the body’s immune system to battle cancer. It helps the immune system recognize and obliterate cancer cells. Dr. Pratik Patil explains that immunotherapy is frequently utilized for cancers like cellular breakdown in the lungs, melanoma, kidney cancer, and certain blood cancers. It is an effective option for patients who may not respond to traditional treatments like chemotherapy. What is the Cost of Immunotherapy? The cost of immunotherapy in Pune depends on the type of cancer and the number of sessions required. On average, the cost can range from ₹2 lakhs to ₹6 lakhs per cycle. Dr. Pratik Patil emphasizes the importance of discussing costs with your oncologist to plan your treatment effectively. Many hospitals in Pune also offer financial assistance programs. Is Immunotherapy for Cancer Successful? Immunotherapy has shown remarkable success in many cases. It can lead to long-term remission, especially in cancers like melanoma and lung cancer. As indicated by Dr. Pratik Patil, achievement relies upon factors like the type and stage of cancer, and the patient’s general wellbeing. Patients in Pune who have gone through immunotherapy under his consideration often report positive results. At What Stage of Cancer is Immunotherapy Used? Immunotherapy can be used at various stages of cancer. It is often recommended for advanced stages, such as stage 3 or stage 4 cancers, where other treatments may not be effective. Dr. Pratik Patil states that early stages can also benefit from immunotherapy, depending on the type of cancer and the patient’s condition. Cancer treatment in Pune is becoming more advanced, thanks to options like immunotherapy. Is Chemo Cheaper than Immunotherapy? Yes, chemotherapy is generally cheaper than immunotherapy. While chemotherapy costs in Pune may range from ₹50,000 to ₹1.5 lakhs per cycle, immunotherapy is more expensive. However, Dr. Pratik Patil highlights that the benefits of immunotherapy, including fewer side effects and improved quality of life, often justify the higher cost. Can Stage 4 Cancer be Cured with Immunotherapy? While immunotherapy may not ensure a remedy for stage 4 cancer, it can fundamentally delay life and work on its quality. Dr. Pratik Patil, Medical oncologists explains that numerous patients in Pune with advanced cancers have experienced remarkable outcomes with immunotherapy. The treatment can shrink tumors, postpone sickness movement, and, at times, lead to abatement. How Long Can a Cancer Patient Live with Immunotherapy? The survival rate with immunotherapy varies. A few patients live for a very long time subsequent to beginning treatment. Dr. Pratik Patil shares that patients in Pune have revealed survival times, particularly for cancers like melanoma and non-small cell lung cancer. The long-term benefits depend on how the cancer responds to the treatment. What Happens After Immunotherapy Ends? After immunotherapy ends, patients may need regular follow-ups to monitor their progress. Side effects like fatigue or skin reactions may take time to subside. Dr. Pratik Patil advises his Pune patients to maintain a healthy lifestyle and attend all follow-up appointments. These steps ensure that any recurrence or side effects are managed promptly. Can Cancer Spread While on Immunotherapy? In some cases, cancer may progress despite immunotherapy. This could happen if the cancer cells develop resistance to the treatment. Dr. Pratik Patil emphasizes the importance of regular monitoring to assess the effectiveness of the treatment. If cancer spreads, alternative treatments can be explored at advanced cancer care centers in Pune. What is the Risk of Death from Immunotherapy? Like any treatment, immunotherapy carries some risks. Severe side effects, such as immune-related complications, can occur. However, Dr. Pratik Patil ensures that his patients in Pune are closely monitored to minimize these risks. He states that the benefits of immunotherapy often outweigh the risks, especially for patients with advanced cancers.

Pembrolizumab Immunotherapy Current & Future of Cancer Treatment Pembrolizumab Immunotherapy is an immune checkpoint inhibitor, a form of immunotherapy, designed to help the immune system target and destroy cancer cells. It is a monoclonal antibody that binds to the programmed cell death 1 (PD-1) protein on T cells, preventing cancer cells from evading immune detection. By blocking this interaction, pembrolizumab enables the immune system to attack and eliminate cancer cells effectively. Initially, it gained accelerated approval from the FDA in September 2014 for treating advanced, refractory melanoma. Since then, pembrolizumab has been approved for several other cancer types, with ongoing clinical trials exploring its potential in additional oncologic conditions. This innovative treatment is accessible right here in Pune! Discover the expertise of Dr. Pratik Patil, recognized as the best oncologist in Pune, specializing in immunotherapy, and can guide you through your cancer treatment options. Read this interesting article on how pembrolizumab transforms treatment across various cancer types. The Role of Pembrolizumab Immunotherapy in Cancer Treatment: Biliary Tract Cancer: Pembrolizumab is used in combination with gemcitabine hydrochloride and cisplatin for biliary tract cancer that is either unresectable or has metastasized. This regimen aims to manage the disease when surgical options are no longer viable. Breast Cancer: For triple-negative breast cancer (TNBC), Pembrolizumab is employed in multiple scenarios: Advanced Stage: It is combined with chemotherapy for patients whose tumors express the PD-L1 protein and are either recurrent, unresectable, or metastatic. Early-Stage: It is used with chemotherapy before surgery and continued alone after surgery in patients with high-risk early-stage TNBC, aiming to reduce recurrence. Classic Hodgkin Lymphoma: Pembrolizumab is used: Adults: For cases that are refractory or have relapsed after initial treatments. Children: For relapsed or refractory cases after at least two other treatment lines. Cervical Cancer: Pembrolizumab’s role in cervical cancer includes: Stage III/IVA: Used alongside chemotherapy and radiation therapy for advanced-stage cervical cancer. Recurrent or Metastatic: Combined with chemotherapy, with or without bevacizumab, for cancers that are PD-L1 positive and have either relapsed or metastasized. PD-L1 Positive Refractory Cases: Administered alone for cancers that have worsened during or after chemotherapy. Cutaneous Squamous Cell Carcinoma: For this skin cancer, Pembrolizumab is indicated in patients whose disease has recurred or spread and is not amenable to surgical or radiation therapy. Endometrial Carcinoma: Pembrolizumab is approved for: Combination Therapy: With carboplatin and paclitaxel followed by monotherapy for patients with advanced or recurrent endometrial cancer. Monotherapy: For MSI-H or dMMR cancers that are not curable by surgery or radiation. Lenvatinib Combination: For cancers that are not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), which have progressed after other therapies. Esophageal and Gastroesophageal Junction Cancer: Pembrolizumab is used: Chemotherapy: Combined with platinum-based chemotherapy and fluoropyrimidine for cancers that cannot be treated with surgery or chemoradiation. As Monotherapy: For squamous cell cancers that are PD-L1 positive, following prior systemic therapy. Gastric Cancer: For advanced gastric or gastroesophageal junction adenocarcinoma: HER2 Positive: Pembrolizumab is used with trastuzumab, fluoropyrimidine, and platinum-based chemotherapy. HER2 Negative: Administered with fluoropyrimidine and platinum-based chemotherapy. Hepatocellular Carcinoma: Pembrolizumab is indicated for patients who have progressed on sorafenib, providing an alternative therapeutic approach for advanced liver cancer. Melanoma: Pembrolizumab is applied in: Advanced Cases: For cancers that are unresectable or metastatic. Adjuvant Therapy: In adults and children aged 12 years and older with stage IIB, IIC, or III melanoma, following surgical resection. Merkel Cell Carcinoma: Pembrolizumab is used for Merkel cell carcinoma that has recurred or spread in both adults and children. Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Cancers Pembrolizumab treats: Solid Tumors: In both adults and children with TMB-H solid tumors have progressed after other treatments and are not amenable to other therapies. Colorectal Cancer: Specific focus on cancers with MSI-H or dMMR characteristics. If you want to explore immunotherapy for your cancer treatment, book an appointment today with Dr. Pratik Patil to discuss your options and take the next step toward your health. https://www.pratikpatil.co.in/pembrolizumab-immunotherapy-current-future-of-cancer-treatment/

Targeted Therapy and Immunotherapy for Gallbladder Cancer As researchers learn more about the changes in cells that cause gallbladder cancer, they’ve developed drugs to target some of these changes. These targeted drugs work differently from standard chemotherapy (chemo) drugs. They sometimes work when standard chemo drugs don’t, and they often have different side effects. FGFR2 inhibitors: FGFRs (fibroblast growth factor receptors) are proteins on cells that help them grow and divide normally. A small number of people with gallbladder cancer have changes in the genes that make FGFRs, which result in abnormal FGFR proteins that cause cells to grow out of control and turn into cancer. Pemigatinib (Pemazyre) and futibatinib (Lytgobi) are FGFR2 inhibitors. They block the abnormal FGFR2 protein in gallbladder cancer cells and keep them from growing and spreading to other places. These drugs can be used to treat some advanced gallbladder cancers that cannot be removed by surgery or have spread to distant areas after at least one previous chemotherapy treatment. For these drugs to work, your cancer must have an abnormal FGFR2 gene, so your cancer will be tested before starting any of these drugs. These medicines are taken by mouth as tablets, typically once a day. IDH1 inhibitor: In some people with gallbladder cancer, the cancer cells have a change (mutation) in the IDH1 gene, which normally helps cells make the IDH1 protein. Mutations in this gene can lead to an abnormal IDH1 protein, which can stop cells from maturing the way they normally would. Ivosidenib (Tibsovo) is an IDH1 inhibitor. It blocks the abnormal IDH1 protein, which seems to help the cancer cells mature into more normal cells. This drug can be used in people with advanced, previously treated gallbladder cancer, if the cancer cells are found to have an IDH1 mutation. Your doctor can test your cancer cells to see if they have an IDH1 mutation. This drug is taken by mouth, once a day. Less common but more serious side effects can include changes in heart rhythm, pneumonia, and jaundice (yellowing of the eyes and skin). NTRK inhibitor: A very small number of gallbladder cancers have changes in one of the NTRK genes, called NTRK gene fusions. Cells with these gene changes make abnormal TRK proteins, which can lead to abnormal cell growth and cancer. Larotrectinib (Vitrakyi) or entrectinib (Rozlytrek) are NTRK inhibitors. TRK inhibitors target and disable the proteins made by the NTRK genes. This drug can be used in people with advanced gallbladder cancer, who have not received prior systemic therapy. These drugs are taken as pills, once or twice daily. Possible side effects of NTRK inhibitors: Common side effects can include abnormal liver tests; decreased white blood cell and red blood cells; muscle and joint pain; tiredness; diarrhea or constipation; nausea and vomiting; and stomach pain. Less common but more serious side effects can include mental changes, such as confusion, changes in mood, changes in sleep; liver damage; changes in heart rhythm and/or function; vision changes; harm to a fetus. RET inhibitor: In a small percentage of gallbladder cancers, the tumor cells have a rearrangement in the RET gene that causes them to make an abnormal form of the RET protein. This abnormal protein helps the tumor cells grow.  Selpercatinib (Retevmo) or pralsetinib (Gayreto) are RET inhibitors and can be used to treat advanced gallbladder cancers with the RET rearrangement. These drugs are taken by mouth as capsules, typically once or twice a day. Possible side effects of RET inhibitors: Common side effects can include dry mouth, diarrhea or constipation, high blood pressure, tiredness, swelling in hands and/or feet, skin rash, muscle and joint pain, low blood cell counts, or changes in other blood tests. Less common but more serious side effects can include liver damage, lung damage, allergic reactions, changes in heart rhythm, bleeding easily, and problems with wound healing. If you need targeted therapy and immunotherapy for gallbladder cancer, please book an appointment with our cancer specialist in Pune, Dr. Pratik Patil. https://www.pratikpatil.co.in/targeted-therapy-and-immunotherapy-for-gallbladder-cancer/

How a Cancer Specialist in Pune Can Help Manage Stage 4 Cancer Are you dealing with a stage 4 cancer diagnosis? It’s completely understandable to feel overwhelmed and uncertain. If you’re seeking cancer treatment in Pune, you don’t have to face this challenge alone. Dr. Pratik Patil, a top cancer specialist in Pune, is committed to offering compassionate care and cutting-edge treatments to support you in your fight against the disease. Stage 4 cancer, or metastatic cancer, is the most advanced stage, where the cancer has spread to other parts of the body. Managing stage 4 cancer requires a complex, multidisciplinary approach. A Medical Oncologist in Pune, like Dr. Pratik Patil, is crucial in delivering comprehensive care, treatment, and support to patients and their families during this difficult time. In this blog, Dr Pratik Patil discusses how a cancer specialist can assist in managing stage 4 cancer and the significance of personalized care in enhancing the quality of life for patients. Understanding Stage 4 Cancer: Stage 4 cancer occurs when cancer cells have spread from the primary site to other organs or distant parts of the body. This process is known as metastasis. Metastasis can occur in the liver, lungs, bones, or brain. At this stage, the cancer is generally considered incurable, but it can still be managed to control symptoms, slow its progression, and improve the patient’s quality of life. The treatment approach for stage 4 cancer is focused on palliative care, which aims to alleviate pain and other symptoms, rather than curative intent. The Role of a Cancer Specialist in Stage 4 Cancer Management: Managing stage 4 cancer involves a multi-faceted approach tailored to each patient’s needs. Dr. Pratik Patil, a leading Cancer Specialist in Pune, plays a crucial role in this process through the following: Personalized Treatment Plan: Stage 4 cancer management is challenging and developing a personalized treatment plan is the most important part of the process. The key factors that make personalization effective are the type of cancer, the extent to which it has metastasized, the patient’s overall health, their personal preferences, etc. Dr. Pratik Patil, an experienced cancer specialist in Pune, uses a person-centered method to adjust treatment plans to meet the specific needs of each patient. This may include a combination of therapies such as chemotherapy, targeted therapy, immunotherapy, and radiation therapy. Chemotherapy: Chemotherapy is generally a significant aspect of the stage 4 cancer treatment process. It could involve using strong medicines that either kill or slow down the cancer cells. The main purpose of chemotherapy is to control the disease, but at the same time, possible side effects are the other side of the coin. Dr. Patil, a cancer specialist, meticulously observes patients during the chemotherapy procedure to control side effects and modify the treatment when necessary. The aim is to achieve the best therapeutic results and at the same time, not cause any suffering to the patient. Targeted Therapy: One of the latest developments in cancer therapy is targeted treatment, which is a method of directing cancer to specific molecules to eliminate cancer cell growth and survival. Chemotherapy is a method that is used to treat cancer both in healthy and cancerous cells, while targeted therapy seeks to disrupt the cancer cell’s ability to grow, divide, and spread. Dr. Pratik Patil employs targeted therapies when suitable because these medications can be more efficient and cause fewer side effects than traditional chemotherapy. Radiation Therapy: Radiation therapy may be used to reduce the size of tumors, relieve pain, and manage other symptoms. Cancer specialists carefully schedule the radiation treatments in a way that will not cause any damage to the healthy tissues. For example, Dr. Patil, a cancer specialist, plans the radiation therapy very carefully and administers it so that it is as effective as possible and at the same time, the surrounding healthy tissues are not damaged. Immunotherapy: This method has come from the contemporary world, it draws on the body’s immune system to combat the cancer cells. Cancer specialists evaluate the patients to decide whether it is advisable to use immunotherapy as a method besides other treatments. https://www.pratikpatil.co.in/how-a-cancer-specialist-in-pune-can-help-manage-stage-4-cancer/